Getinge publish Interim Report January - September 2017
”We can report a positive trend in the order intake for the third quarter, although I am not satisfied with earnings, which were put under pressure by both lower net sales and higher operating expenses. Net sales were adversely impacted by the lower order intake in the second quarter and higher expenses partly related to the work on preparing the proposed distribution of the Patient & Post-Acute Care business area. We are also continuing to invest in product development, sales and quality, as we have previously announced”, says Mattias Perjos, President & CEO.
July – September 2017 in brief
- Order intake increased by 2.2% to SEK 7,334 M (7,176). The order intake increased organically by 4.7%.
- Net sales fell by 3.4% to SEK 6,696 M (6,929). Net sales decreased organically by 0.7%.
- Cash flow from operating activities declined 18.3% to SEK 592 M (725). The cash conversion was 66.4% (89.5).
- EBITA 1* declined by 31.6% to SEK 659 M (963).
- Restructuring and integration costs amounted to SEK 234 M (732).
- Profit after financial items increased to SEK 77 M (-110).
- Earnings per share increased to SEK 0.20 (-0.36).
- Rights issue completed, providing Getinge with approximately SEK 4.3 billion and the interest-bearing net debt being reduced to SEK 17.6 billion (23.3).
- Order intake increased by 2.6% to SEK 22,122 M (21,560). The order intake increased organically by 0.5%.
- Net sales increased by 1.8% to SEK 20,601 M (20,233). Net sales fell organically by 0.2%.
- Cash flow from operating activities declined by 10.9% to SEK 1,683 M (1,888). The cash conversion was 58.7% (68.1).
- EBITA 1* decreased by 1.3% to SEK 2,341 M (2,371).
- Restructuring and integration costs amounted to SEK 854 M (992).
- Profit after financial items increased to SEK 469 M (358).
- Earnings per share increased to SEK 1.35 (1.01).
January – September 2017 in brief
- Order intake increased by 2.6% to SEK 22,122 M (21,560). The order intake increased organically by 0.5%.
- Net sales increased by 1.8% to SEK 20,601 M (20,233). Net sales fell organically by 0.2%.
- Cash flow from operating activities declined by 10.9% to SEK 1,683 M (1,888). The cash conversion was 58.7% (68.1).
- EBITA 1* decreased by 1.3% to SEK 2,341 M (2,371).
- Restructuring and integration costs amounted to SEK 854 M (992).
- Profit after financial items increased to SEK 469 M (358).
- Earnings per share increased to SEK 1.35 (1.01).
* EBITA 1: EBITA before acquisition, restructuring and integration costs. See definition on report page 24.
Conference call
Fund managers, analysts and media are invited to participate in the conference call at 15:00 CET, hosted by Mattias Perjos, President & CEO, and Niclas Sjöswärd, Interim CFO. Please find dial in details to join the conference here.
For further information, please contact:
Jeanette Hedén Carlsson, EVP Communications & Brand Management
Phone: +46 (0)10 335 1003
Email: jeanette.hedencarlsson@getinge.com
Lars Mattsson, Head of Investor Relations
Phone: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com
This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on October 18, 2017.
About Getinge
Getinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our firsthand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people - today and tomorrow.
Tags:
